Aa
Effect of Peginterferon Alfa-2a (Pegasys) on Liver Histology in Chronic HCV
This is very good news and adds evidence to the histolgic effects of interferon.
If anyone doesn't achieve the "12 week 2 log drop" magic number this is a good study to show to the doctors if they want you to stop treatment.
If anyone doesn't achieve the "12 week 2 log drop" magic number this is a good study to show to the doctors if they want you to stop treatment.
Well, gee ...
You're saying that a patient's liver who is 'cured' (and let's define 'cure' to equal a sustained virologic response) becomes worse two years out? Or do you mean in non-responders? THAT I could see but in responders? I know of people that attain a SVR that go on to develop HCC ... yes, but how many? Not too many, more than likely. If the virus is not attacking the liver why would the fibrosis progress? Do we have some data showing that to be the case 2-4 years out? Dr. Hoofnagel says that this "may" happen? I am not clear on it.
You're saying that a patient's liver who is 'cured' (and let's define 'cure' to equal a sustained virologic response) becomes worse two years out? Or do you mean in non-responders? THAT I could see but in responders? I know of people that attain a SVR that go on to develop HCC ... yes, but how many? Not too many, more than likely. If the virus is not attacking the liver why would the fibrosis progress? Do we have some data showing that to be the case 2-4 years out? Dr. Hoofnagel says that this "may" happen? I am not clear on it.
You really are a Honey. You could not have picked a better name. I promise not to make any drastic decisions. Thank you again for reaching out. May Gods graces continue to be with you. Sincerely, Edgar
You said that Dr. Dieterich didn't know what he was talking about re: interferon crossing the blood/brain barrier.
Your statement:
"With all due respect to Doug Dietrick, he is not a neurologist. The researchers doing this work are: Forton in the UK, Aronow (a neurovirologist) in the USA, Firenza in Switzerland.
"Since I am not a doctor and certainly not a researcher in neurovirology, I can only tell you that Dr. Aronow has personally told me that the size of the pegylated molecule is too large to cross the blood brain barrier.
"You can ask Dr. dietrick the question, but sadnly, I cannot agree that his expertise extends into this area. It could, though. Maybe he knows something the other researchers don't know.
"thanbey"
You are saying he doesn't know what he's talking about without coming right out and saying those exact words. That suggestion is absurd.
You mean his peers wouldn't have corrected him? That would be laughable except your wrong-headed assertions could possibly steer people away from treatment.
I don't know what your agenda is but, as is often said, the truth will set us free. If you have some data contradicting Dieterich let's see it.
Take care,
Scott
Your statement:
"With all due respect to Doug Dietrick, he is not a neurologist. The researchers doing this work are: Forton in the UK, Aronow (a neurovirologist) in the USA, Firenza in Switzerland.
"Since I am not a doctor and certainly not a researcher in neurovirology, I can only tell you that Dr. Aronow has personally told me that the size of the pegylated molecule is too large to cross the blood brain barrier.
"You can ask Dr. dietrick the question, but sadnly, I cannot agree that his expertise extends into this area. It could, though. Maybe he knows something the other researchers don't know.
"thanbey"
You are saying he doesn't know what he's talking about without coming right out and saying those exact words. That suggestion is absurd.
You mean his peers wouldn't have corrected him? That would be laughable except your wrong-headed assertions could possibly steer people away from treatment.
I don't know what your agenda is but, as is often said, the truth will set us free. If you have some data contradicting Dieterich let's see it.
Take care,
Scott
With all due respect to Doug Dietrick, he is not a neurologist. The researchers doing this work are: Forton in the UK, Aronow (a neurovirologist) in the USA, Firenza in Switzerland.
Since I am not a doctor and certainly not a researcher in neurovirology, I can only tell you that Dr. Aronow has personally told me that the size of the pegylated molecule is too large to cross the blood brain barrier.
You can ask Dr. dietrick the question, but sadnly, I cannot agree that his expertise extends into this area. It could, though. Maybe he knows something the other researchers don't know.
thanbey
Since I am not a doctor and certainly not a researcher in neurovirology, I can only tell you that Dr. Aronow has personally told me that the size of the pegylated molecule is too large to cross the blood brain barrier.
You can ask Dr. dietrick the question, but sadnly, I cannot agree that his expertise extends into this area. It could, though. Maybe he knows something the other researchers don't know.
thanbey
my email is ***@****
been trying to send email unsuccessfully... Edgar
Again thank you for your research on non-responders.
been trying to send email unsuccessfully... Edgar
Again thank you for your research on non-responders.
Douglas T. Dieterich, MD, Contributing Editor
Dr. Dieterich is Vice Chair and Chief Medical Officer Department of Medicine at The Mount Sinai Medical Center. He is also an attending physician at New York University Tisch Hospital, a clinical assistant attending at Bellevue Hospital Center, and an attending physician at Beth Israel North.
A graduate of Yale University, Dr. Dieterich received his medical degree from New York University School of Medicine, and completed his internship and residency in the Department of Internal Medicine, Bellvue Hospital Center.
A fellow of the American College of Physicians and the American College of Gastroenterology, Dr. Dieterich is a member of several professional societies. He has also served on several committees of the AIDS Clinical Trials Group (ACTG) and the National Institutes of Health (NIH), including as a member of the steering committee of the Opportunistic Infections Core Committee, and a member of the Cytomegalovirus (CMV) Committee. He has also served on the NIH Study Sections for CMV and cryptosporidiosis.
Dr. Dieterich has authored numerous journal articles, abstracts, and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal tract and liver, and their treatment. He is an internationally-recognized expert on hepatitis C infection and is involved in several research programs evaluating the management treatment of chronic hepatitis C virus (HCV) infection and co-infection with HIV/HCV.
---------------------------
Dieterich doesn't know what he is talking about? Hmmm ...
As I stated before: If you have some proof contradicting the doctor's statement re: the blood brain barrier let us see it. If not I believe the matter is settled.
Dr. Dieterich is Vice Chair and Chief Medical Officer Department of Medicine at The Mount Sinai Medical Center. He is also an attending physician at New York University Tisch Hospital, a clinical assistant attending at Bellevue Hospital Center, and an attending physician at Beth Israel North.
A graduate of Yale University, Dr. Dieterich received his medical degree from New York University School of Medicine, and completed his internship and residency in the Department of Internal Medicine, Bellvue Hospital Center.
A fellow of the American College of Physicians and the American College of Gastroenterology, Dr. Dieterich is a member of several professional societies. He has also served on several committees of the AIDS Clinical Trials Group (ACTG) and the National Institutes of Health (NIH), including as a member of the steering committee of the Opportunistic Infections Core Committee, and a member of the Cytomegalovirus (CMV) Committee. He has also served on the NIH Study Sections for CMV and cryptosporidiosis.
Dr. Dieterich has authored numerous journal articles, abstracts, and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal tract and liver, and their treatment. He is an internationally-recognized expert on hepatitis C infection and is involved in several research programs evaluating the management treatment of chronic hepatitis C virus (HCV) infection and co-infection with HIV/HCV.
---------------------------
Dieterich doesn't know what he is talking about? Hmmm ...
As I stated before: If you have some proof contradicting the doctor's statement re: the blood brain barrier let us see it. If not I believe the matter is settled.
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
